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Epoxyeicosatrienoic acids (EETs), lipid mediators produced by
cytochrome P450 epoxygenases, regulate inflammation, angio-
genesis, and vascular tone. Despite pleiotropic effects on cells, the
role of these epoxyeicosanoids in normal organ and tissue re-
generation remains unknown. EETs are produced predominantly
in the endothelium. Normal organ and tissue regeneration require
an active paracrine role of the microvascular endothelium, which
in turn depends on angiogenic growth factors. Thus, we hypoth-
esize that endothelial cells stimulate organ and tissue regeneration
via production of bioactive EETs. To determine whether endothe-
lial-derived EETs affect physiologic tissue growth in vivo, we used
genetic and pharmacological tools to manipulate endogenous EET
levels. We show that endothelial-derived EETs play a critical role in
accelerating tissue growth in vivo, including liver regeneration,
kidney compensatory growth, lung compensatory growth, wound
healing, corneal neovascularization, and retinal vascularization.
Administration of synthetic EETs recapitulated these results, whereas
lowering EET levels, either genetically or pharmacologically, delayed
tissue regeneration, demonstrating that pharmacological modula-
tion of EETs can affect normal organ and tissue growth. We also
show that soluble epoxide hydrolase inhibitors, which elevate en-
dogenous EET levels, promote liver and lung regeneration. Thus,
our observations indicate a central role for EETs in organ and tissue
regeneration and their contribution to tissue homeostasis.
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Endogenously produced lipid autacoids—locally acting lipidmediators—play a central role in the response to tissue injury
(1). Products of arachidonic acid metabolism (eicosanoids), in-
cluding prostaglandins and leukotrienes, are generated by dis-
tinct enzymatic systems initiated by cyclooxygenase (COX) and
lipoxygenase (LOX) (2, 3). There is, however, another prom-
inent enzymatic pathway for which arachidonic acid is the sub-
strate: the cytochrome P450 (CYP) system (2). This eicosanoid
pathway consists of two main branches: ω-hydroxylases, which
convert arachidonic acid into hydroxyeicosatetraenoic acids, and
epoxygenases, which convert it to epoxyeicosatrienoic acids
(EETs) (4, 5). Although the COX- and LOX-derived eicosanoids
have been intensely studied in tissue regeneration (6, 7), the
investigation of CYP-derived eicosanoids has primarily focused
on inflammation and cardiovascular functions (3).
EETs are lipid mediators produced by CYP epoxygenases
(CYP2C8 and CYP2J2 in humans) and metabolized by soluble
epoxide hydrolase (sEH) to the corresponding dihydroxyeicosa-
trienoic acids (2). Endothelial cells (ECs) contribute to tissue
mass regulation, including the growth of adipose tissue, normal
prostate, and bone, by supplying oxygen and nutrients to the
growing tissue via neovascularization. However, ECs, which ex-
press CYP epoxygenases and sEH, also act through paracrine
(trophic) effects on these growing tissues (8–10). In the vascu-
lature, bioactive EETs are produced predominantly in the en-
dothelium (8). ECs play a critical role in the development of
a vascular network, tissue growth, and regenerative processes,
including wound healing, corneal neovascularization, neonatal
retinal vessel formation, and liver and lung regeneration (8, 11).
The human liver can generate high EET levels, mostly 14,15- and
11,12-EET, as well as abundant sEH (12). Modulation of liver
sEH may therefore permit the increase or decrease of EET
levels, as observed in response to inflammatory signals (13).
EETs have anti-inflammatory effects and stimulate vasodila-
tion, cellular proliferation, migration, and angiogenesis (8).
Nevertheless, the role of these epoxyeicosanoids in normal
tissue growth, such as organ regeneration, has not been
studied. Normal tissue and organ regeneration require an active
microvascular endothelium that provides trophic support (11). For
instance, liver or lung regeneration requires angiocrine signals
from the sinusoidal or pulmonary endothelium, respectively (14,
15). Although the roles of many growth factors/cytokines have
been characterized in liver and lung regeneration (14, 15), EETs
have not been implicated in organ regeneration to date. Thus,
given that EETs are produced by the microvasculature, we hy-
pothesized that the endothelial-derived EETs can promote tis-
sue and organ regeneration via pleomorphic effects.
Recent studies have shown that EETs stimulate tissue growth
in culture and in animal studies. EETs enhance axonal growth in
neuronal cell cultures (16). Mice with targeted gene deletion of
sEH have increased plasma EETs and exhibit a larger pancreatic
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islet size (17). Moreover, local administration of EETs accel-
erates wound epithelialization and neovascularization in a mouse
ear-wound model (18). However, the role of endothelial-derived
EETs in tissue regeneration remains poorly characterized. To
determine whether endothelial-derived EETs play a role in phys-
iologic tissue growth, we used genetic and pharmacological tools to
manipulate endogenous EET levels in seven well-characterized
animal models: (i) liver regeneration, (ii) kidney compensatory
growth, (iii) lung compensatory growth, (iv) angiogenesis Matrigel
plug assay, (v) corneal micropocket assay, (vi) wound healing, and
(vii) neonatal retinal vessel formation. Here, we report that EETs
accelerate tissue growth and organ regeneration. The production
of EETs in the endothelium might thus be a critical paracrine
mediator, revealing a unique trophic function for the endothelium
in stimulating tissue growth.
Results
Endothelial-Derived EETs Promote Liver Regeneration, as Well as
Kidney and Lung Compensatory Growth. To determine whether
EET autacoids produced by the endothelium promote tissue
growth, we have generated three lines of transgenic mice with high
endothelial EET levels: mice with endothelial (Tie2-promoter
driven) expression of either human CYP2C8 or human CYP2J2
(Tie2-CYP2C8-Tr and Tie2-CYP2J2-Tr) and mice with global
disruption of the gene that encodes sEH (sEH-null) (19). Tie2-
CYP2C8-Tr and Tie2-CYP2J2-Tr mice have significantly in-
creased endothelial EETs compared with wild-type (WT) mice,
as measured by liquid chromatography–tandem mass spec-
trometry (LC-MS/MS) (19, 20), and sEH-null mice have sig-
nificantly increased plasma EETs (21). In contrast, COX- and
LOX-derived metabolites are unaffected in these mice (20). To
characterize the impact of reduced endothelial EETs, we also
generated a unique murine model with endothelial expression
of human sEH (Tie2-sEH-Tr) (22). ECs isolated from these
mice have significantly decreased EET levels relative to ECs
isolated from WT mice (20).
Organ regeneration is controlled, in part, by the microvascular
endothelium (11, 14, 15). To determine whether EETs are nat-
urally up-regulated during liver regeneration, we performed LC-
MS/MS analysis of plasma from mice undergoing partial hepa-
tectomies (removal of two-thirds of the murine liver). Plasma
14,15-, 11,12-, 8,9-, and 5,6-EET were elevated by 300%, 305%,
225%, and 222%, respectively, when measured 12 h after partial
hepatectomy (Fig. 1A). Similarly, human donors undergoing
partial liver resections for living-related liver transplantation
have a 1.5- to 3-fold increase in 14,15-EET levels 1–7 d after
donor liver hepatectomy (Fig. 1B).
To determine whether endothelial-derived EETs affect liver
regeneration, we performed partial hepatectomies in Tie2-
CYP2C8-Tr and WT mice. By day 4 after partial hepatectomy,
Tie2-CYP2C8-Tr mice exhibited a 32% increase in the liver/body
weight ratio compared with WT controls (Fig. 1C). In contrast,
there were no significant differences in liver/body weight ratio at
baseline or after sham operation. Histological analysis of the
Tie2-CYP2C8-Tr livers revealed increased hepatocyte pro-
liferation characterized by thickening of the hepatocyte cords,
multinucleation, and increased nuclear size—features that are
typical of dividing cells in a regenerating liver (Fig. S1A). EC
proliferation was increased in the livers from Tie2-CYP2C8-Tr
mice compared with WT mice as determined by immunofluo-
rescent double staining for vessels [anti-mouse panendothelial
cell antigen-32 (MECA-32)] and proliferation (Ki-67) (Fig. 1D).
Because angiogenesis is necessary for regeneration and EETs
have been shown to stimulate angiogenesis via VEGF (20, 23),
we next analyzed the livers from Tie2-CYP2C8-Tr and WT mice
on day 4 after hepatectomy for VEGF. Livers from Tie2-
CYP2C8-Tr mice exhibited an increase in VEGF expression
compared with WT mice (Fig. S1B).
Trichrome staining of livers revealed increased collagen de-
position in the basement membrane of blood vessels in livers
from the Tie2-CYP-Tr mice compared with WT mice (Fig. S1C),
consistent with acceleration of liver regeneration with new and
functional liver tissue. We next isolated liver sinusoidal ECs and
demonstrated that both 11,12-EET (1 μM) and 14,15-EET (1 μM)
stimulate liver EC proliferation from 45% to 81%, respectively
(Fig. S1D).
To determine whether endothelial-derived EETs stimulate
kidney compensatory growth, we performed unilateral nephrec-
tomies in Tie2-CYP2C8-Tr and WT mice. Kidney compensa-
tory growth was significantly increased in Tie2-CYP2C8-Tr mice
Fig. 1. Endothelial-derived EETs promote liver, kidney, and lung re-
generation. (A) Plasma 14,15-, 11,12-, 8,9-, and 5,6-EET are elevated 12 h
after partial hepatectomy. *P < 0.05 vs. day 0. (B) The 14,15-EET levels are
increased 1–7 d after human donor liver hepatectomy in humans un-
dergoing living-related donor liver resections for recipients undergoing liver
transplantation. *P < 0.05 vs. day 0. (C) Liver regeneration is accelerated in
Tie2-CYP2C8-Tr mice on day 4 after partial hepatectomy. n = 5 mice per
group. *P < 0.05 vs. WT. Representative photos are shown. (Scale bars, 1 cm.)
(D) Immunofluorescent double staining for MECA-32 and proliferating cell
nuclear antigen (PCNA) shows increased EC proliferation in livers from Tie2-
CYP2C8-Tr vs. WT mice on day 4 after partial hepatectomy. Red, MECA-32-
stained ECs; green, PCNA-stained proliferating cells. Colocalization of red
and green fluorescence (yellow) indicates proliferating ECs. (Scale bars, 20
μm.) (E) Kidney regeneration is significantly increased in Tie2-CYP2C8-Tr
mice 21 d after partial nephrectomy. n = 5–8 mice per group. *P < 0.05 vs.
WT. (F) Lung regeneration is significantly increased in Tie2-CYP2C8-Tr mice
4 d after left pneumonectomy. n = 5 mice per group. *P < 0.05 vs. WT.











compared with WT mice on day 21 (Fig. 1E). To determine
whether endothelial-derived EETs also stimulate lung compen-
satory growth, we performed unilateral pneumonectomies and
observed a 23% increase in contralateral lung growth on day 4
following left pneumonectomy in Tie2-CYP2C8-Tr compared
with WT mice (Fig. 1F).
Pharmacological Manipulation of EETs and Their Action in Organ
Regeneration. To demonstrate that EETs are sufficient to pro-
mote organ regeneration and to unambiguously show that the
organ-regenerative effect was specific to EETs, and not mediated
by other downstream effects of CYP enzymes, we administered
14,15- or 11,12-EET to mice by osmotic minipump. Consistent
with our results in the Tie2-CYP2C8-Tr mice, systemic adminis-
tration of 14,15-EET significantly increased the liver/body weight
ratio by 46% compared with vehicle-treated mice (Fig. 2A).
Similarly, systemic administration of 11,12-EET increased liver/
body weight ratio by 23% relative to vehicle control (Fig. 2A).
To confirm the observed effects of exogenous EETs and to es-
tablish the clinical relevance of pharmacological EET modulation,
we next characterized the effect of EET modifying compounds in
liver regeneration and lung compensatory growth models. We first
studied compounds that increase EETs by inhibiting sEH, the main
metabolizing enzyme of EETs. Notably, several structurally distinct
sEH inhibitors (sEHis) are being evaluated for clinical indi-
cations (3, 24, 25). Systemic administration of the sEHi 1-(1-
methylsulfonyl-piperidin-4-yl)-3-(4-trifluoromethoxy-phenyl)-urea
(TUPS, UC1709) increased liver regeneration by 38% com-
pared with vehicle-treated mice (Fig. 2B) and also increased
lung growth by 23% (Fig. 2C).
To corroborate the specificity of these findings, we next sought
to block the action of EETs. Although the receptor(s) for EETs has
not yet been identified (3), the EET antagonist 14,15-epoxyeicosa-5
(Z)-enoic acid (14,15-EEZE) is the most specific reagent available
for pharmacologic suppression of EET activity (26) and has been
used to antagonize the biological effects of EETs in other disease
models (20, 23). To determine whether an EET antagonist could
inhibit organ regeneration, we administered 14,15-EEZE following
partial hepatectomy. Mice treated with 14,15-EEZE demonstrated
reduced liver regeneration (Fig. 2D). Thus, pharmacological mod-
ulation of EET levels recapitulates the results obtained in geneti-
cally engineeredmice with respect to stimulation and suppression of
tissue and organ regeneration. Collectively, these observations
demonstrate that tissue regeneration is significantly stimulated by
endothelial EETs, an effect that is likely promoted by EET-de-
pendent regulation of angiogenesis.
EETs stimulate VEGF production in livers undergoing liver
regeneration (Fig. S1B). To identify the source of VEGF, we
analyzed livers from VEGF–LacZ-transgenic mice treated with
14,15-EET or vehicle (in these mice the LacZ reporter is in-
troduced into the VEGF locus) as described (20). In VEGF–
LacZ-transgenic mice systemically treated with 14,15-EET, liver
sinusoidal, and vein ECs and hepatocytes stained positive for
the LacZ product β-galactosidase, whereas in vehicle-treated
VEGF–LacZ-transgenic mice, this marker for VEGF production
was absent in the liver sinusoidal ECs and reduced in hep-
atocytes (Fig. 2E). To further determine whether VEGF-stimu-
lated angiogenesis plays a functional role in EET-stimulated liver
regeneration, we depleted VEGF by expressing a soluble form of
the VEGF receptor 1 (sFlt) using an adenoviral delivery system.
In vehicle-treated mice, which have low systemic VEGF levels,
VEGF depletion had no significant effect on liver regeneration
(Fig. 2F). In contrast, in mice treated with tAUCB, which have
elevated plasma 14,15-EET levels by LC-MS/MS analysis (Fig.
S2A), VEGF depletion suppressed the accelerated liver re-
generation induced by sEHi {trans-4-[4-(3-adamantan-1-ylureido)
cyclohexyloxy]-benzoic acid (tAUCB, UC1471)} (Fig. 2F). Thus,
EETs required VEGF for liver regeneration. Using VEGF–
LacZ-transgenic mice, we show that liver sinusoidal ECs and
hepatocytes treated with EETs can generate VEGF and that the
proliver regenerative activity of EETs is mediated by VEGF
production.
Endothelial-Derived EETs Stimulate Tissue Vascularization and Corneal
Neovascularization. To determine whether the modulation of
endothelial-derived EETs directly affected tissue vascularization
in vivo, we used two well-characterized animal models: angio-
genesis Matrigel plug assay and corneal micropocket assay (27–
29). Matrigel plugs implanted into WT mice (negative control) in
the absence of exogenous growth factors demonstrated no
stimulation of blood vessels. Compared with WT mice, sEH-null,
Tie2-CYP2J2-Tr, and Tie2-CYP2C8-Tr mice each exhibited
Fig. 2. Pharmacological manipulation of EETs and their action in organ re-
generation. (A) Systemic administration of 14,15- or 11,12-EET (15 μg·kg−1·d−1)
via minipump stimulates liver regeneration on day 4 after partial hepa-
tectomy compared with vehicle-treated mice. n = 5 mice per group. *P <
0.05 vs. vehicle. (B) The sEHi TUPS increases liver regeneration at day 4 after
partial hepatectomy. TUPS was given at a dose of 10 mg·kg−1·d−1. n = 5
mice per group. *P < 0.05 vs. control. (C) The sEHi TUPS increases lung re-
generation at day 4 after partial pneumonectomy. TUPS was given at a dose
of 10 mg·kg−1·d−1. n = 5 or 6 mice per group. *P < 0.05 vs. control. (D)
Systemic administration of the EET antagonist 14,15-EEZE (0.21 mg per
mouse) inhibits liver regeneration on day 7 after partial hepatectomy. n = 5
mice per group. *P < 0.05 vs. control. (E) Regenerating livers in VEGF–LacZ-Tr
mice treated with 14,15-EET (15 μg·kg−1·d−1) show β-galactosidase staining
(marker of VEGF production) in sinusoidal and venous ECs (arrows) and
hepatocytes. (Scale bars, 100 μm.) (F) VEGF depletion with Ad-sFlt suppresses
EET-induced liver regeneration by the sEHi tAUCB but has no effect on ve-
hicle-treated liver regeneration. n = 5 mice per group. *P < 0.05.
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pronounced invasion of ECs into the plug. This result was in-
dicated by a striking increase in CD31-positive microvessels
when analyzed by whole-mount immunofluorescent staining
(Fig. 3A), consistent with the proangiogenic effects of EETs and
the increased vascularization previously observed in sEH-null
mice (17, 30). These results also correlate with the plasma 14,15-
EET levels that we recently reported in these different trans-
genic mice strains (20). Flow cytometry quantification of disso-
ciated cells revealed a 4- to 15-fold increase in CD31-positive
cells in the plugs from Tie2-CYP2J2-Tr, Tie2-CYP2C8-Tr, and
sEH-null mice compared with WT mice (Fig. 3B). Conversely, in
plugs from Tie2-sEH-Tr mice, there was a nearly 40% decrease
in the number of infiltrating ECs compared with WT mice
(Fig. 3B). Thus, mice genetically engineered to have reduced en-
dothelial EETs showed reduced angiogenesis in this assay.
We recently demonstrated that VEGF signaling is required for
EET-induced tumor angiogenesis (20). To determine whether
VEGF or fibroblast growth factor 2 (FGF-2) contributed to
EETs’ stimulated angiogenesis in regeneration, we performed
corneal micropocket assays in Tie2-CYP2C8-Tr and WT mice.
Implantation of FGF-2 or VEGF-containing pellets stimulated
corneal neovascularization over 6 d in WT animals, as we and
others have reported (29). The vessel length and area of neo-
vascularization induced by FGF-2 in Tie2-CYP2C8-Tr mice was
unchanged relative to WT mice (Fig. S2B). In contrast, VEGF-
stimulated angiogenesis in Tie2-CYP2C8-Tr mice was increased
by ∼60% compared with WT mice, reflected by increased vessel
length and neovascularization area (Fig. S2C).
Endothelial-Derived EETs Accelerate Wound Healing and Stimulate
Neonatal Retinal Vessel Formation. Because the endothelium and
VEGF both play a pivotal role in wound healing (31), we next
examined the role of the endothelial-derived EETs in wound
healing. By manipulating EET levels in the tissue, as opposed to
local administration in the wound in methylcellulose discs [as
reported (18)], we examined the systemic role of EETs in wound
healing. Wound healing was accelerated in Tie2-CYP2J2-Tr,
Tie2-CYP2C8-Tr, and sEH-null mice compared with WT mice 1
wk after tissue injury (Fig. 4A). Immunohistochemical analysis
revealed more mature wounds in the genetically altered mice
with granulation tissue that was progressively more organized
(i.e., healing) and increased vascularization compared with WT
mice (Fig. 4B and Fig. S3A). By contrast, wound healing in Tie2-
sEH-Tr mice (reduced endothelial EETs) was suppressed (Fig.
4A). Analysis of the time course revealed that there was a delay
in wound healing in the Tie2-sEH-Tr mice (Fig. S3B). To de-
termine whether systemic administration of EETs would accel-
erate wound healing, we administered EETs (14,15- or 11,12-
EET) via miniosmotic pump. Systemic administration of either
14,15- or 11,12-EET stimulated wound healing (Fig. S3C).
Sander et al. recently demonstrated that local application of
EETs and the sEHi tAUCB accelerates epithelialization and
neovascularization in healing wounds (18). Consistent with these
results, we now show that topical application of sEHi TUPS, as
a cream or systemic administration, accelerated wound healing
(Fig. S3D).
To further study the role of endothelial-derived EETs on
tissue vascularization, we examined a physiological model of
neonatal retinal vessel formation. Consistent with EETs’ stimu-
lating corneal neovascularization and wound healing, the total
area of newly formed microvessels in the neonatal retina, which
is also tightly regulated by VEGF and its receptors (32), was
significantly increased in Tie2-CYP2C8-Tr compared with WT
mice on postnatal day 5 (Fig. S3E).
Discussion
Using genetic and pharmacological means to manipulate en-
dogenous EET levels, we show that these lipid autacoids play
a critical role in accelerating tissue growth, including neonatal
retinal vessel formation, corneal neovascularization, liver regen-
eration, kidney and lung compensatory growth, and wound
healing. We demonstrate that tissue regeneration, including or-
gan regeneration and wound healing, is dependent on endothe-
lial-derived EETs. Production of EETs in the endothelium might
thus be a critical regulator of tissue growth. Although we show
that the endothelium, acting as a source of local EETs, is a major
regulator of tissue and organ regeneration, our studies with ex-
ogenously administrated 14,15- and 11,12-EET indicate that high
levels of systemic EETs can also stimulate tissue growth.
Tissue repair and regeneration are partially mediated by an-
giogenesis (11, 33, 34). Here we show that the role of the en-
dothelium extends beyond neovascularization to include the
endothelial paracrine effect of EETs on tissue regeneration. The
endothelium (and the supporting stroma) also secrete angiogenic
factors (14, 35). This process establishes a positive feedback loop
ensuring sustained trophic support by endothelium-derived fac-
tors (14, 35). For example, VEGF and FGFs induce angiogenesis
in wounds and skin regeneration (36). Our studies show that
VEGF-mediated neovascularization is enhanced in mice with
high endothelial-derived EETs, consistent with the results ob-
tained by others (23). Local administration of EETs was recently
shown to accelerate wound epithelialization and neovasculari-
zation in a mouse ear-wound model (18). We confirmed this
finding using topical application of the sEHi TUPS as well as by
systemic administration of 14,15- and 11,12-EET by miniosmotic
pump. These strategies should be investigated to improve wound
healing in humans. Recent advances in tissue engineering and
drug delivery, such as scaffolds (37), to deliver growth factors for
vascularized tissue-engineering therapies might be optimized to
improve prolonged delivery of EETs, which have a short half-life
(3), for tissue and organ regeneration.
Like wound healing, organ regeneration is a tissue repair re-
sponse (38). However, the precise signals and mechanisms of
organ regeneration remain elusive. Lipid autacoids such as
COX-derived prostaglandin E2 have been implicated in wound
healing, organ regeneration, and the repair of gastrointestinal
ulcers in animal models (6). Accumulating experimental evi-
dence suggests an essential role of angiogenesis for organ de-
velopment and regeneration. Most studies have focused on the
role of stimulating organ regeneration with VEGF and other
Fig. 3. Endothelial-derived EETs stimulate tissue vascularization. (A) Whole-mount immunofluorescent CD31 staining of Matrigel plugs with no growth factors
added shows increased vascularization in Tie2-CYP2J2-Tr, Tie2-CYP2C8-Tr, and sEH-null mice vs. WT mice. (Scale bars, 100 μm.) (B) Matrigel plug angiogenesis,
quantified by flow cytometry, showing relative fraction of CD31+/CD45− ECs infiltrated into the plug. EC numbers (relative toWT) are increased in Tie2-CYP2J2-Tr,
Tie2-CYP2C8-Tr, and sEH-null mice and decreased in Tie2-sEH-Tr mice relative to WT mice. n = 6–8 plugs per group. *P < 0.05 vs. WT.











angiogenic growth factor and cytokine-related mechanisms. Af-
ter hepatectomy, hepatocyte regeneration is stimulated by VEGF
(39). VEGF induces liver sinusoidal ECs to secrete growth and
survival factors such as hepatocyte growth factor and IL-6 that
result in hepatocyte proliferation (35), again underscoring the
trophic function of the endothelium. Our studies suggest that
EETs are an important paracrine growth and survival factor in
liver regeneration.
The role of such angiocrine growth factors is not unique to
liver regeneration. VEGF, but not FGF-2, accelerates compen-
satory lung growth after unilateral pneumonectomy (40). How-
ever, two selective VEGF receptor inhibitors had no effect on
lung regeneration, suggesting that VEGF is not the only regu-
lator of tissue regeneration (40). Our data suggest that EETs also
play an important role in lung tissue repair. Impaired lung re-
generation is present in life-threatening diseases such as bron-
chopulmonary dysplasia and congenital diaphragmatic hernia in
premature infants (40). Several studies support the notion that
ECs within the lungs actively promote normal alveolar growth
and lung regeneration (15). Conversely, genetic or pharmaco-
logical antagonism of the VEGF nitric oxide pathway can lead to
decreased lung angiogenesis and poor lung regeneration (41).
Similar to the liver and lung regeneration discussed above, kidney
blood vessels appear to have a role in kidney regeneration (42).
Consistent with our findings in liver regeneration and lung com-
pensatory growth, EETs stimulated kidney compensatory growth.
Although angiogenesis is an important target of EETs, we
show that the endothelium acts as a source for angiocrine trophic
factors and that EETs appear to play a prevalent role in this
process. EETs may have direct trophic effects on the stem cell
compartment to account for their stimulatory actions on tissue
regeneration. For instance, chemokines, such as stromal cell-de-
rived factor 1 (SDF-1), have been shown to play a role in mes-
enchymal stem cell (MSC) homing in therapeutic angiogenesis,
wound healing, and liver regeneration, as well as neuronal re-
generation (43). Because EETs were recently shown to up-regulate
SDF-1α and VEGF in healing wounds (18), it will be important to
determine whether EETs alter other factors that influence wound
repair. Furthermore, sEHis have been shown to stimulate axonal
growth in neuronal cell cultures (16). An EET agonist was recently
reported to stimulate MSC-derived adipocyte proliferation and
differentiation (44), suggesting a role in adipose regeneration.
Our results offer a mechanistic rationale for evaluating sEHis
as novel therapeutics for a number of human diseases, such as
hepatic insufficiency after liver damage or surgical resection in
various liver disorders including trauma or infection. In addition,
sEHis could have therapeutic efficacy in diseases characterized by
immature lung development such as bronchopulmonary dysplasia.
Topical sEHis could also be useful in accelerating wound healing
in both diabetic and nondiabetic populations. The pharmacologi-
cally accessible EET autacoid system offers an entirely unique
approach to enhance normal tissue growth, thus accelerating criti-
cal life-saving processes, such as organ regeneration and wound
healing. However, in seeking to increase the level or activity of
EETs for therapeutic indications, it will be important to balance
these beneficial effects with our finding that direct administra-
tion of exogenous EETs can also stimulate cancer growth in
preclinical models (20).
Materials and Methods
Generation of Tie2-CYP2J2, Tie2-CYP2C8, and Tie2-sEH Transgenic Mice. Trans-
genic mice were generated as described (19, 22).
Reagents. The 14,15- and 11,12-EET were obtained from Cayman Chemical.
The 14,15-, 11,12-EET or vehicle were administered intraperitoneally via
osmotic minipump (Alzet) at a dose of 15 μg·kg−1·d−1. TUPS was synthesized
as described (24, 25), and TUPS was completely dissolved in PEG 400 at
a concentration of 10 mg/mL and mixed into Vanicream to obtain a 0.1%
(wt:vol) formulated cream. The sEHi (TUPS) was administered orally by ga-
vage in an aqueous solution of 10% (vol/vol) DMSO in 0.5% methylcellulose
(10 mg·kg−1·d−1) or as a 0.1% cream applied topically; control mice received
vehicle. The EET antagonist 14,15-EEZE (0.21 mg per mouse) was adminis-
tered as we recently described (20).
Tissue Homeostasis and Angiogenesis Assays. All animal studies were reviewed
and approved by the Institutional Animal Care and Use Committee of Boston
Children’s Hospital. Genetically modified mice with high EET (Tie2-CYP2C8-Tr,
Tie2-CYP2J2-Tr, and sEH-null) or low EET (Tie2-sEH-Tr) levels were compared
with WT littermate control mice. Six-month-old male mice were used. In vivo
Matrigel plug whole-mount staining of CD31 was performed as described (27).
Briefly, Matrigel (Becton-Dickinson) (400 μL) was injected on each side of the
ventral midline with sphingosine-1-phosphate (1 μM). Matrigel plugs were
collected on day 7. Fluorescent staining (CD31) of Matrigel plug sections was
performed as described (27). Quantification of ECs in the Matrigel plugs
was performed by FACS following enzymatic digestion of the Matrigel plugs
as described (28). Flow cytometry was performed by using FACS Calibur
and CellQuest software (BD Biosciences). ECs were defined as CD31+/
CD45− cells. Corneal neovascularization assays (80 ng of FGF2 or 160 ng of
VEGF) were performed as described (29). For wound-healing studies, two 8-mm
dermal punch biopsy wounds were performed per mouse. Wound area was
quantified via computerized analysis with IP-LAB software (Scanalytics). Partial
hepatectomy and unilateral pneumonectomy were performed as we described
(33, 45). For the unilateral nephrectomies, the kidneywas isolated, renal pedicle
was ligated, and the kidney was excised. For systemic administration of 14,15-
and 11,12-EET,male C57BL/6Jmice (Jackson Laboratories) were used. For in vivo
VEGF depletion, Ad-null and Ad-sFlt were administered systemically as de-
scribed (20). Mouse liver ECs were isolated from 8- to 10-wk old nude mice.
Excised mouse liver tissues were processed to make single cell suspension. The
cells were then incubated with anti-mouse CD31 antibody (eBioscience), and
Fig. 4. Endothelial-derived EETs accelerate wound
healing and stimulate neonatal retinal vessel for-
mation. (A) Wound healing is accelerated in Tie2-
CYP2J2-Tr, Tie2-CYP2C8-Tr, and sEH-null mice, and
suppressed in Tie2-sEH-Tr mice, relative to WT as
quantified by wound area after 7 d. *P < 0.05 vs.
WT. n = 10–12 wounds per group. (Scale bars, 1 cm.)
(B) Hematoxylin and eosin (H&E)-stained sections of
wounds in Tie2-CYP2J2-Tr and Tie2-CYP2C8-Tr mice
on day 7 reveals more mature wounds with collagen
deposition with granulation compared with WT
mice. (Scale bars, 100 μm.)
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liver ECs were isolated by MACS (Miltenyi Biotec) according to the manu-
facturer’s protocol, using anti-rat IgG microbeads (Miltenyi Biotec). They were
plated onto 1.5% gelatin-coated culture plates and grown in microvascular
endothelial cell growth medium 2 (EGM-2MV) (Lonza). To improve the
purity of liver ECs, magnetic sorting was performed by using two MACS
columns set up in series. For mouse liver EC proliferation, mouse liver ECs
were seeded at 2 × 105 cells into a plate with different concentrations of
EET. Cell number was counted every day for 3 d. The data are presented as
the average of three different well counts ± SEM for each group. The ex-
periment was repeated three times.
Immunohistochemistry. Wound and liver samples were processed and immu-
nohistochemical stainings were performed as we described (46). For rat platelet
endothelial cell adhesion molecule (PECAM-1; CD31), sections were treated
with 40 μg/mL proteinase K (Roche Diagnostics) for 25min at 37 °C as described
(47). Rat anti-mouse PECAM-1 (Pharmingen; 1:250), MECA-32 rat anti-
mouse panendothelial cell antigen (Pharmingen; 1:250), and proliferating
cell nuclear antigen (PCNA; Vector; 1:50), and VEGF rabbit (Thermo Sci-
entific; 1:100) were incubated at 4 °C overnight. MECA-32 and PCNA
staining was completed as we described (29). β-Galactosidase staining was
performed as described (20).
LC-MS/MS Analysis. ECs were isolated from WT, Tie2-CYP2J2-Tr, Tie2-CYP2C8-
Tr, and Tie2-sEH-Tr mice, and LC-MS/MS analysis was performed as described
(19, 20, 22). All human studies were reviewed and approved by the In-
stitutional Review Board at Lahey Clinic Medical Center. Informed consent
was obtained from the human donors. Plasma samples (n = 53) were
obtained from five human donors undergoing partial liver resections for
living-related liver transplantation.
Statistical Analysis. The Student’s two-sided unpaired t test was used to
analyze the difference between the two groups. P < 0.05 were considered
statistically significant. Data are presented as mean ± SEM.
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